NightHawk Biosciences laid off 14% of its workforce in R&D in order to focus on its contract development and manufacturing organization (CDMO), just...
The race to develop new therapies that precisely edit short-lived RNA molecules instead of making irreversible changes to DNA is heating up. A new entrant...
Seeing the successes of other covalent medicines companies, a group of blue-chip investors is lining up to take the next shot on goal. RA Capital, typically...
Arialys is developing an antibody therapeutic, ART5803, to treat anti-NMDA receptor encephalitis (ANRE), one of the most common forms of autoimmune encephalitis....
PHILADELPHIA—(Sep. 18, 2023)—Zachary Schug, Ph.D., assistant professor in the Molecular and Cellular Oncogenesis Program of the Ellen and Ronald Caplan...
Reston, VA—A new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal...
HOUSTON ― Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective...
TARRYTOWN, NY — For over three decades, Regeneron has been synonymous with one thing in the drug industry: antibodies. Blockbusters like Dupixent, Eylea,...
A cancer drug could play an important role in limiting the damaging effects of lung disease in COVID-19 patients, thanks to new research at Hudson Institute...
New research has shed light on why immune checkpoint blockade immunotherapy does not always work in some cancers with a high tumor mutational burden. The...
Two Phase III biotechs will join the Nasdaq Friday morning, with radiopharma startup RayzeBio and brain disease drug developer Neumora raising $311 million...
Recommendations from the Standards for Human Stem Cell Use in Research, published in June by the International Society for Stem Cell Research (ISSCR),...
A new study has shed light on why immunotherapy does not always work in certain types of cancer. Led by researchers at EMBL’s European Bioinformatics...
New company AlveoGene, backed by experts at the UK Respiratory Gene Therapy Consortium (GTC), has made its debut with a lead program for rare respiratory...
Credit: Insilico Medicine ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine’s...
BIRMINGHAM, Ala. – In the summer of 2018, graduate student Hunter Dean from the Medical Scientist Training Program came to Yuhua Song, Ph.D., with a...
Researchers have invented a nano-thin superbug-slaying material that could one day be integrated into wound dressings and implants to prevent or heal bacterial...
The discovery of a previously unknown molecular target has inspired what may become a therapeutic breakthrough for people with glioblastoma, the most common...
A Deeper Dive Into The Role Of Spike Protein In Myocarditis And Blood Clotting After COVID-19 Vaccination Authored by Allison Kruig, MPH and...
Developing new drugs is paramount in discovering innovative treatments and preventing diseases. This is vital not only for advancing medicine but also...
A few days after the launch of Superluminal Medicines was announced on August 28, CEO Cony D'Cruz told GEN about the company's journey, which started as...
When Richard O’Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR-T-cell therapy...
Despite advances in developing radiopharmaceuticals, manufacturing such drugs remains a challenge. One startup’s plan to tackle the issue is beginning...
Biogen has appointed Jane Grogan as its new head of research. The move comes after CEO Chris Viehbacher said earlier this year he would split up...
PITTSBURGH – To reimagine existing preclinical trials for Alzheimer’s disease, University of Pittsburgh School of Medicine neuroscientists created...
Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of August 28. Aside from presenting a synopsis of events, we provide market...
Canadian next-generation psychedelics developer Mindset Pharma MSSTF has entered into a definitive agreement by which Otsuka America Inc., the U.S....
From Cambridge, U.K., to Cambridge, MA, and from creating better cytokines to aiding gene therapy, the development of new amino acids is likely to open...
David Khougazian It’s a classic biopharma story. In January, David Khougazian bumped into Flagship Pioneering founder Noubar Afeyan at the JP Morgan...
Canadian next-generation psychedelics developer Mindset Pharma MSSTF has entered into a definitive agreement by which Otsuka America Inc., the U.S....